Priority was given to compounds that are able to cross the blood–brain barrier or indirectly modulate central nervous system redox homeostasis, have been consistently reported to influence key pathogenic pathways in Alzheimer’s disease, such as amyloid-β deposition, tau phosphorylation, mitochondrial dysfunction, or neuroinflammation, and represent substances with translational potential due to their availability as dietary components or nutraceuticals. The gene discussed is MAPT; the disease is Alzheimer disease.